Differing Viewpoints: Does FDA Need More Post-Market Authority?
This article was originally published in The Gray Sheet
Executive Summary
Consumer and patient advocates say FDA needs more post-market authorities from Congress for 510(k)-cleared devices, but manufacturers argue that the agency should be able to work with what it has.
You may also be interested in...
Institute Of Medicine On 510(k) Review Program: Dump It
The Institute of Medicine committee charged with reviewing FDA's 510(k) device pre-market review program is urging the agency to ditch the 35-year-old program and start fresh.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.